[go: up one dir, main page]

MA41432A - PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES - Google Patents

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

Info

Publication number
MA41432A
MA41432A MA041432A MA41432A MA41432A MA 41432 A MA41432 A MA 41432A MA 041432 A MA041432 A MA 041432A MA 41432 A MA41432 A MA 41432A MA 41432 A MA41432 A MA 41432A
Authority
MA
Morocco
Prior art keywords
treatment
pharmaceutical composition
gastrointestinal diseases
gastrointestinal
diseases
Prior art date
Application number
MA041432A
Other languages
French (fr)
Inventor
Young Ho Jo
Jun Woo Lee
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55169799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41432(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of MA41432A publication Critical patent/MA41432A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/245Bismuth; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA041432A 2015-01-30 2016-01-27 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES MA41432A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150015339 2015-01-30
KR1020150147513A KR101583452B1 (en) 2015-01-30 2015-10-22 A pharmaceutical composition for treating gastrointestinal diseases

Publications (1)

Publication Number Publication Date
MA41432A true MA41432A (en) 2017-12-05

Family

ID=55169799

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041432A MA41432A (en) 2015-01-30 2016-01-27 PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

Country Status (19)

Country Link
EP (1) EP3250199A4 (en)
JP (1) JP6419347B2 (en)
KR (2) KR101583452B1 (en)
CN (1) CN107205947B (en)
AR (1) AR105413A1 (en)
CL (1) CL2017001680A1 (en)
CO (1) CO2017006222A2 (en)
EA (1) EA032385B9 (en)
EC (1) ECSP17038599A (en)
GE (1) GEP20196941B (en)
MA (1) MA41432A (en)
MX (1) MX2017007567A (en)
MY (1) MY195824A (en)
PE (1) PE20171340A1 (en)
PH (1) PH12017550051A1 (en)
SA (1) SA517382016B1 (en)
TW (1) TWI635859B (en)
UA (1) UA116517C2 (en)
WO (1) WO2016122226A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101988479B1 (en) 2017-10-11 2019-09-24 (주)휴럼 Litsenolide used as an active ingredient for gastrointestinal disease, and A composition comprising the same as an active ingredient
KR102286499B1 (en) * 2018-04-13 2021-08-05 주식회사 삼양홀딩스 Pharmaceutical composition comprising lenalidomide

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282132B1 (en) * 1987-03-09 1992-09-30 The Procter & Gamble Company Compositions and their use for treating gastrointestinal disorders
US4990610A (en) * 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
EP0403048A3 (en) * 1989-06-14 1991-01-30 Warner-Lambert Company Medicated compositions containing sucralfate and processes for their production
KR970006083B1 (en) * 1992-01-22 1997-04-23 주식회사 대웅제약 A pharmaceutical composition for treating gastrointestinal disorders
ES2173183T3 (en) * 1994-04-26 2002-10-16 Chugai Pharmaceutical Co Ltd GRANULATED AND CASTED SUCRALFATE PREPARATION PROCEDURE.
JPH0879097A (en) * 1994-09-01 1996-03-22 Matsushita Electric Ind Co Ltd Portable radio equipment
KR970006083A (en) 1995-07-06 1997-02-19 한승준 Installation structure of wire fixing device of automobile cowl
WO1999010000A1 (en) * 1997-08-25 1999-03-04 The Procter & Gamble Company Combined preparations for treating upper gastrointestinal tract distress
AU4655199A (en) * 1999-06-21 2001-01-09 Dae Woong Pharmaceutical Co., Ltd. Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate
JP2006076956A (en) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk Compounding agent for treating/preventing gastritis
JP5516401B2 (en) * 2008-07-01 2014-06-11 ライオン株式会社 Solid oral preparation
KR20110105223A (en) * 2010-03-18 2011-09-26 일양약품주식회사 Oral pharmaceutical compositions for the prevention or treatment of gastrointestinal diseases containing ilaprazole and a mixture of sucralate and bismuth preparations
KR20140072673A (en) * 2012-12-05 2014-06-13 (주)한국파비스제약 Oral tablet for treatment of gastrointestinal disease

Also Published As

Publication number Publication date
EP3250199A4 (en) 2018-08-08
AR105413A1 (en) 2017-10-04
JP6419347B2 (en) 2018-11-07
EA032385B9 (en) 2019-07-31
SA517382016B1 (en) 2021-03-18
BR112017013857A2 (en) 2018-02-27
UA116517C2 (en) 2018-03-26
JP2018503672A (en) 2018-02-08
CO2017006222A2 (en) 2017-09-20
KR101583452B9 (en) 2022-05-02
GEP20196941B (en) 2019-01-10
EA032385B1 (en) 2019-05-31
KR101583452B1 (en) 2016-01-11
WO2016122226A2 (en) 2016-08-04
ECSP17038599A (en) 2017-09-29
KR20160094268A (en) 2016-08-09
TWI635859B (en) 2018-09-21
WO2016122226A3 (en) 2016-09-15
PE20171340A1 (en) 2017-09-13
EA201791458A1 (en) 2017-11-30
MY195824A (en) 2023-02-22
TW201639559A (en) 2016-11-16
CL2017001680A1 (en) 2018-01-12
MX2017007567A (en) 2017-10-19
CN107205947A (en) 2017-09-26
PH12017550051A1 (en) 2018-01-29
EP3250199A2 (en) 2017-12-06
CN107205947B (en) 2020-05-22

Similar Documents

Publication Publication Date Title
EP3431105A4 (en) MEDICINAL COMPOSITION FOR THE TREATMENT OF CANCER
MA45481A (en) USE OF EXOSOMES FOR THE TREATMENT OF DISEASES
EP3370703A4 (en) COMBINATION OF GEMCABEN FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
EP3227330C0 (en) TDP-43-BINDING POLYPEPTIDES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EP3390634A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR DISEASES
MA47719A (en) ESKETAMINE FOR THE TREATMENT OF DEPRESSION
MA55629A (en) ANTIBODY COMPOSITIONS FOR THE TREATMENT OF TUMORS
MA41449A (en) POLYTHERAPIES FOR THE TREATMENT OF CANCERS
MA39748A (en) CENICRIVIROC FOR THE TREATMENT OF FIBROSIS
EP3436002A4 (en) PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF CANCER
MA44875A (en) COMPOSITIONS FOR THE TREATMENT OF ACID BASIC DISORDERS
EP3374502A4 (en) METHODS FOR THE TREATMENT OF CORNEAL DYSTROPHIES
MA53568A (en) DRUGS FOR THE TREATMENT OF OPHTHALMIC DISEASES
EP3344325A4 (en) LOCAL ADMINISTRATION OF MEDICINES FOR THE TREATMENT OF ASTHMA
EP3316887A4 (en) GLS1 INHIBITORS FOR THE TREATMENT OF DISEASES
EP3378484A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CARDIAC FIBROSIS
EP3766497A4 (en) MEDICINE FOR THE TREATMENT OF COUGH
MA42999A (en) POLYTHERAPY FOR THE TREATMENT OF MALIGNITIES
EP3288565A4 (en) EXTRACELLULAR MATRIX COMPOSITION FOR THE TREATMENT OF CANCER OR IMMUNOLOGICAL DISEASES
EP3363450A4 (en) CHINESE TRADITIONAL MEDICINE COMPOSITION FOR THE TREATMENT OF PSORIASIS
EP3383497A4 (en) NEW ANTIBODIES FOR THE TREATMENT OF CANCERS
EP3347032A4 (en) TREATMENT OF ASCITE
MA46086A (en) DOSAGE SCHEDULE FOR THE TREATMENT OF SOLID TUMORS
EP3373931A4 (en) HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES
MA42930A (en) TREATMENT OF NEURODEGENERATIVE DISEASES